Steven Mah
Stock Analyst at TD Cowen
(1.99)
# 2,967
Out of 4,876 analysts
30
Total ratings
31.03%
Success rate
7.87%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $35.93 | +61.42% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $21.50 | +44.19% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $9.46 | +1,168.50% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $5.03 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $20.61 | +103.78% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.61 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.70 | +488.24% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.62 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.39 | +778.66% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $167.96 | -7.72% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.24 | +2,158.06% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $19.68 | +611.38% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.29 | +3,931.01% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $94.79 | +337.81% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $28.87 | +765.95% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $35.93
Upside: +61.42%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $21.50
Upside: +44.19%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $9.46
Upside: +1,168.50%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $5.03
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $20.61
Upside: +103.78%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.61
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.70
Upside: +488.24%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.62
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.39
Upside: +778.66%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $167.96
Upside: -7.72%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $1.24
Upside: +2,158.06%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $19.68
Upside: +611.38%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.29
Upside: +3,931.01%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $94.79
Upside: +337.81%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $28.87
Upside: +765.95%